Table 2

Cost effectiveness (CE): government perspective

2 year time frame, cohort with baseline best corrected visual acuity = 20/40
	Placebo	Verteporfin	Difference	CE ratio
Cost (£ sterling)	1275	6490	5215
Vision years	1.618	1.773	0.155	33 645
QALYs	1.136	1.205	0.069	75 580

2 year time frame, cohort with baseline best corrected visual acuity = 20/100
	Placebo	Verteporfin	Difference	CE ratio
Cost (£ sterling)	4590	8878	4288
Vision years	1.074	1.383	0.309	13 877
QALYs	0.980	0.995	0.015	285 867

5 year time frame, cohort with baseline best corrected visual acuity = 20/40
	Placebo	Verteporfin	Difference	CE ratio
Cost (£ sterling)	10 200	11 700	1500
Vision years	2.160	3.050	0.890	1685
QALYs	2.205	2.375	0.170	8823

5 year time frame, cohort with baseline best corrected visual acuity = 20/100
	Placebo	Verteporfin	Difference	CE ratio
Cost (£ sterling)	15,700	18,500	2,800
Vision years	1.222	1.858	0.636	4,402
QALYs	1.999	2.093	0.094	29,787